Canadian CRO Cirion Biopharma has been acquired by Cerba HealthCare in a deal that expands the French clinical trial lab and diagnostics provider’s offerings and geographic reach.

加拿大CRO Cirion Biopharma已被Cerba HealthCare收购，扩大了法国临床试验实验室和诊断提供商的产品和地理范围。

With the deal, Cerba gains Cirion’s bioanalytical capabilities in biosimilars and biologics development, including pharmacokinetic-pharmacodynamic (PKPD) and immunogenicity testing, experience in managing international multicenter clinical studies and specimen management support for complex development projects, the companies said in a Sept.

通过这项交易，Cerba获得了Cirion在生物仿制药和生物制剂开发方面的生物分析能力，包括药代动力学-药效学（PKPD）和免疫原性测试，管理国际多中心临床研究和复杂开发项目标本管理支持的经验。

7 press release..

7新闻稿。。

Cirion, which has more than 80 employees, also provides R&D services ranging from preclinical drug discovery through to phase IV trial drug development. Financial terms of the deal weren’t disclosed.

Cirion拥有80多名员工，还提供从临床前药物发现到IV期试验药物开发的研发服务。协议的财务条款没有披露。

“I see Cirion as a true strategic step in improving our offering both geographically and scientifically,” Cerba Research CEO Mario Papillon said in the release. “It deepens our North American presence while featuring sound expertise in PKPD assay development and testing, which is instrumental knowledge for our customers as it relates drug concentration to drug effect.”.

Cerba研究首席执行官Mario Papillon在该版本中说：“我认为Cirion是改善我们在地理和科学方面的真正战略步骤。“它加深了我们在北美的存在，同时在PKPD分析开发和测试方面拥有完善的专业知识，这对于我们的客户来说是工具性的知识，因为它将药物浓度与药物效应联系起来。”。

Under terms of the deal, Cirion will become part of Cerba Research, a unit of Cerba HealthCare. The acquisition is just the latest in a string of M&A in the CRO space in recent weeks. This has included London-based private equity firm Permira shelling out 703 million pounds sterling ($886 million) to take U.K.-based CRO Ergomed private as well as Singapore-based Harvest Integrated Research Organization acquiring Minnesota-based CRO oncology specialist Courante Oncology..

根据协议条款，Cirion将成为Cerba HealthCare部门Cerba Research的一部分。最近几周，这项收购只是CRO空间的一系列并购中的最新一次。这包括伦敦的私募股权公司Permira推出7.03亿英镑（8.86亿美元），收购英国的CRO-Ergomed私人公司以及新加坡的Harvest综合研究组织，收购明尼苏达州的CRO-oncology专家Courante oncology。。